Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
TRENARY C RUSSELL III
  2. Issuer Name and Ticker or Trading Symbol
ABBOTT MEDICAL OPTICS INC [EYE]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
former Exec VP
(Last)
(First)
(Middle)
C/O ABBOTT MEDICAL OPTICS INC., 1700 E. ST. ANDREW PLACE
3. Date of Earliest Transaction (Month/Day/Year)
02/25/2009
(Street)

SANTA ANA, CA 92705
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/25/2009   U   7,699.6791 (1) D $ 22 759.6096 (2) D  
Common Stock 02/26/2009   D   759.6096 (3) D $ 22 0 D  
Common Stock 02/25/2009   A   496 (4) A $ 0 496 D  
Common Stock 02/25/2009   F   227 (5) D $ 22.01 269 D  
Common Stock 02/26/2009   D   269 (3) D $ 22 0 D  
Common Stock 02/25/2009   A   2,540 (6) A $ 0 2,540 D  
Common Stock 02/25/2009   F   1,163 (5) D $ 22.01 1,377 D  
Common Stock 02/26/2009   D   1,377 (6) D $ 22 0 D  
Common Stock 02/25/2009   A   3,451 (6) A $ 0 3,451 D  
Common Stock 02/25/2009   F   1,579 (5) D $ 22.01 1,872 D  
Common Stock 02/26/2009   D   1,872 (6) D $ 22 0 D  
Common Stock 02/25/2009   A   1,879 (6) A $ 0 1,879 D  
Common Stock 02/25/2009   F   860 (5) D $ 22.01 1,019 D  
Common Stock 02/26/2009   D   1,019 (6) D $ 22 0 D  
Common Stock 02/26/2009   D   1.5162 (3) D $ 22 0 I Shares had been held by 401(k) Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 33.72 02/26/2009   D(7)     50,000 05/20/2008 05/20/2014 Common Stock 50,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 38.2 02/26/2009   D(8)     50,000 05/26/2009 05/26/2019 Common Stock 50,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 45.26 02/26/2009   D(9)     39,000 05/24/2010 05/24/2016 Common Stock 39,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 42.55 02/26/2009   D(10)     55,900 05/21/2011 05/21/2017 Common Stock 55,900 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 22.94 02/26/2009   D(11)     50,000 05/29/2012 05/29/2018 Common Stock 50,000 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
TRENARY C RUSSELL III
C/O ABBOTT MEDICAL OPTICS INC.
1700 E. ST. ANDREW PLACE
SANTA ANA, CA 92705
      former Exec VP

Signatures

 C. Russell Trenary III, By: Aimee S. Weisner, Attorney in Fact   02/27/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These shares were tendered to Rainforest Acquisition Inc. ("Purchaser") pursuant to Purchaser?s offer to purchase all of the outstanding shares of Advanced Medical Optics, Inc. (the "Issuer") at a cash purchase price of $22.00 per share, without interest, and subject to any required withholding taxes, subject to the terms described in the Offer to Purchase, filed with the SEC on January 27, 2009, as amended (the "Tender Offer"). Such shares were purchased by Purchaser pursuant to the Tender Offer on February 25, 2009.
(2) Includes an aggregate of 759.6096 shares of common stock acquired through the issuer's Employee Stock Purchase Plan through October 31, 2008.
(3) These shares were canceled pursuant to the Agreement and Plan of Merger, dated January 11, 2009, by and among Abbott Laboratories, Purchaser and the Issuer (the "Merger Agreement"), in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes) at the effective time of the merger.
(4) Exempt restricted shares of common stock forfeited in connection with termination of employment were reinstated pursuant to change in control agreement.
(5) Shares withheld in satisfaction of tax obligations attributable to the lapse of restrictions on stock award or in satisfaction of tax withholding attributable to vesting and settlement of restricted stock units.
(6) The exempt restricted stock units (previously reported on Table II) that had been forfeited in connection with the reporting person's termination of employment were reinstated pursuant to a change in control agreement, vested in full and were settled for shares of Issuer Common Stock in accordance with the terms of the applicable equity plan. At the effective time of the merger, such shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes).
(7) This previously reported exempt stock option, which had vested ratably over four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 20,514 shares of Abbott Laboratories common stock at an exercise price of $82.19 per share, determined pursuant to a formula set forth in the Merger Agreement.
(8) This previously reported exempt stock option, which became 100% vested on December 31, 2008 in connection with the reporting person's termination of employment, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 20,514 shares of Abbott Laboratories common stock at an exercise price of $93.11 per share, determined pursuant to a formula set forth in the Merger Agreement.
(9) This previously reported exempt stock option, which became 100% vested on December 31, 2008 in connection with the reporting person's termination of employment, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 16,001 shares of Abbott Laboratories common stock at an exercise price of $110.32 per share, determined pursuant to a formula set forth in the Merger Agreement.
(10) This previously reported exempt stock option, which became 100% vested on December 31, 2008 in connection with the reporting person's termination of employment, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 22,935 shares of Abbott Laboratories common stock at an exercise price of $103.71 per share, determined pursuant to a formula set forth in the Merger Agreement.
(11) This previously reported exempt stock option, which became 100% vested on December 31, 2008 in connection with the reporting person's termination of employment, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 20,514 shares of Abbott Laboratories common stock at an exercise price of $55.92 per share, determined pursuant to a formula set forth in the Merger Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.